Target Name: ATF3
NCBI ID: G467
Other Name(s): Activating transcription factor 3, transcript variant 1 | Activating transcription factor 3, transcript variant 3 | ATF3 variant 1 | Activating transcription factor 3 | activating transcription factor 3 | cAMP-dependent transcription factor ATF-3 | ATF3 variant 3 | Cyclic AMP-dependent transcription factor ATF-3 (isoform 1) | Cyclic AMP-dependent transcription factor ATF-3 | ATF3_HUMAN | ATF-3

Exploring the Potential Drug Target ATF3: Activating Transcription Factor 3 and its Potential Applications

Introduction

ATF3, also known as Activating Transcription Factor 3, is a critical transcription factor that plays a vital role in various cellular processes. It is a protein that is expressed in various tissues and cell types and is known to regulate gene expression by activating or repressing the activity of other transcription factors. ATF3 has been identified as a potential drug target and has been studied extensively in the context of various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Diseases and Their Significance

ATF3 is involved in various cellular processes that are crucial for the normal functioning of the cell. One of its most significant functions is in the regulation of cell growth and differentiation. ATF3 has been shown to play a critical role in the regulation of cell cycle progression , and it has been shown to disrupt the normal cell cycle in various diseases, including cancer.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, ATF3 has been shown to be involved in the regulation of neurotransmitter synthesis and release. It has also been shown to play a role in the regulation of cellular stress responses, which are critical for maintaining the health and function of the brain.

In addition to its role in cellular stress responses and cell cycle regulation, ATF3 has also been shown to play a critical role in the regulation of gene expression. It has been shown to activate various transcription factors, including NF-kappa-B, AP-1, and STAT3, and to regulate the expression of various genes, including genes involved in cell adhesion, migration, and survival.

Potential Drug Target

The potential drug target for ATF3 is based on its role in the regulation of various cellular processes and its involvement in the development of various diseases. ATF3 has been shown to be involved in the regulation of cancer cell growth and survival, and it has been identified as a potential therapeutic target for various types of cancer, including breast, ovarian, and prostate cancers.

In addition to its potential use as a cancer therapeutic, ATF3 has also been identified as a potential biomarker for various types of cancer. The expression of ATF3 has been shown to be increased in various types of cancer, including breast, ovarian, and prostate cancers , and it has been used as a biomarker for these diseases.

Studies have also shown that inhibiting the activity of ATF3 may have potential therapeutic benefits for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In these diseases, ATF3 has been shown to play a critical role in the regulation of neurotransmitter synthesis and release, and inhibiting its activity may be a potential therapeutic approach.

Conclusion

In conclusion, ATF3 is a protein that plays a critical role in various cellular processes and has been identified as a potential drug target and biomarker for various types of diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the role of ATF3 in these diseases and to develop effective therapies that target its activity.

Protein Name: Activating Transcription Factor 3

Functions: This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Represses transcription from promoters with ATF sites. It may repress transcription by stabilizing the binding of inhibitory cofactors at the promoter

More Common Targets

ATF4 | ATF4P2 | ATF4P4 | ATF5 | ATF6 | ATF6-DT | ATF6B | ATF7 | ATF7IP | ATF7IP2 | ATG10 | ATG101 | ATG12 | ATG13 | ATG14 | ATG16L1 | ATG16L2 | ATG2A | ATG2B | ATG3 | ATG4A | ATG4B | ATG4C | ATG4D | ATG5 | ATG7 | ATG9A | ATG9B | ATIC | ATL1 | ATL2 | ATL3 | ATM | ATMIN | ATN1 | ATOH1 | ATOH7 | ATOH8 | ATOSA | ATOSB | ATOX1 | ATOX1-AS1 | ATP Synthase, H+ Transporting, Mitochondrial F0 complex | ATP synthase, H+ transporting, mitochondrial F1 complex | ATP-Binding Cassette (ABC) Transporter | ATP-dependent 6-phosphofructokinase | ATP10A | ATP10B | ATP10D | ATP11A | ATP11A-AS1 | ATP11AUN | ATP11B | ATP11C | ATP12A | ATP13A1 | ATP13A2 | ATP13A3 | ATP13A3-DT | ATP13A4 | ATP13A5 | ATP13A5-AS1 | ATP1A1 | ATP1A1-AS1 | ATP1A2 | ATP1A3 | ATP1A4 | ATP1B1 | ATP1B2 | ATP1B3 | ATP1B4 | ATP23 | ATP2A1 | ATP2A1-AS1 | ATP2A2 | ATP2A3 | ATP2B1 | ATP2B1-AS1 | ATP2B2 | ATP2B3 | ATP2B4 | ATP2C1 | ATP2C2 | ATP4A | ATP4B | ATP5F1A | ATP5F1B | ATP5F1C | ATP5F1D | ATP5F1E | ATP5F1EP2 | ATP5IF1 | ATP5MC1 | ATP5MC1P3 | ATP5MC2 | ATP5MC3 | ATP5ME | ATP5MF | ATP5MG | ATP5MGL